RxDoctor Payments Data

Primo Andres, MD

Cardiology · Terre Haute, INNPI 1538132808

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,776 of the $4,462 with a category attached, or 62.2%. 18 manufacturers reported payments, led by Medtronic at 48.5% of the total. Reporting peaked in 2019 at $2,427 and has fallen 93.6% since, to $156 in 2025.

$4,462in general payments, 2019–2025

Across 55 payments — averaging $81.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$1K
  • Pfizer$135
  • Novo Nordisk$122
  • Teva Pharmaceuticals USA, Inc.$105
  • Abbott$102
  • plus $378 from 12 others

What the payments were for

  • Travel & lodging$2,77662%
  • Food & beverage$1,64737%
  • Education$401%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cardiology providers in Indianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$199,683
Medicare patients
460
Services billed
2,237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin240$259,152
EliquisApixaban191$182,747
FarxigaDapagliflozin Propanediol163$141,013
MultaqDronedarone Hcl109$139,220
EntrestoSacubitril/Valsartan115$126,186
XareltoRivaroxaban85$76,270
Repatha SureclickEvolocumab70$68,049
BrilintaTicagrelor19$24,210
Ranolazine ErRanolazine120$15,154
MounjaroTirzepatide13$13,929
VerquvoVericiguat15$13,711
JanuviaSitagliptin Phosphate14$10,917
Praluent PenAlirocumab12$9,028
Atorvastatin Calcium675$6,823
Isosorbide Mononitrate ErIsosorbide Mononitrate492$6,093

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$135$182,747191 claims
AstraZenecaFarxiga, Brilinta$73$165,223182 claims
NovartisEntresto$18$126,186115 claims
Johnson & JohnsonXarelto$43$76,27085 claims
MerckVerquvo, Januvia$19$24,62829 claims
Lilly USA, LLCMounjaro$20$13,92913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in Indianaon file to place this against a meaningful peer group, so we don't.

Other cardiology in Terre Haute

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →